Anti-Human GFRAL Reference Antibody (NGM120)
- Catalog number: BS11525
- Availability: In Stock
$370.00
- Ex Tax: $370.00
Description: Anti-Human GFRAL (NGM120) (BS11525) is a research-grade recombinant antibody targeting C6orf144. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: C6orf144,GDNFfamilyreceptoralpha-like,GFRAL
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: NGM120
Background: GDNF family receptor alpha-like (GFRAL) is a ~44 kDa protein. Brainstem-restricted receptor for GDF15 hormone, which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses. The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future. The GDF15-GFRAL aversive response is triggered by stresses, such as anticancer drugs (camptothecin or cisplatin), cancers or drugs such as metformin. Upon interaction with its ligand, GDF15, mediates the GDF15-induced autophosphorylation and activation of the RET tyrosine kinase receptor, leading to activation of MAPK- and AKT- signaling pathways. Ligand-binding activates GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem.
References:
1. Mullican, SE. et al. (2017) Nature medicine 23, 1150-1157. PMID: 28846097
2. Emmerson, PJ. et al. (2017) Nature medicine 23, 1215-1219. PMID: 28846098
3. Yang, L. et al. (2017) Nature medicine 23, 1158-1166. PMID: 28846099
4. Hsu, JY. et al. (2017) Nature 550, 255-259. PMID: 28953886
5. Benichou, O. et al. (2023) Cell metabolism 35, 274-286.e10. PMID: 36630958
6. Li, J. et al. (2019) eLife 8. PMID: 31535977
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: C6orf144,GDNFfamilyreceptoralpha-like,GFRAL
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: NGM120
Background: GDNF family receptor alpha-like (GFRAL) is a ~44 kDa protein. Brainstem-restricted receptor for GDF15 hormone, which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses. The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future. The GDF15-GFRAL aversive response is triggered by stresses, such as anticancer drugs (camptothecin or cisplatin), cancers or drugs such as metformin. Upon interaction with its ligand, GDF15, mediates the GDF15-induced autophosphorylation and activation of the RET tyrosine kinase receptor, leading to activation of MAPK- and AKT- signaling pathways. Ligand-binding activates GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem.
References:
1. Mullican, SE. et al. (2017) Nature medicine 23, 1150-1157. PMID: 28846097
2. Emmerson, PJ. et al. (2017) Nature medicine 23, 1215-1219. PMID: 28846098
3. Yang, L. et al. (2017) Nature medicine 23, 1158-1166. PMID: 28846099
4. Hsu, JY. et al. (2017) Nature 550, 255-259. PMID: 28953886
5. Benichou, O. et al. (2023) Cell metabolism 35, 274-286.e10. PMID: 36630958
6. Li, J. et al. (2019) eLife 8. PMID: 31535977
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SDS-PAGESDS-PAGE for Research Grade Anti-Human GFRAL (NGM120).
-
Western blot
